Drug intelligence / Profile preview

AMP-423

Development stage: Preclinical
Lead developer: Eddingpharm
Modality: Peptides
Administration: Subcutaneous

Overview

AMP-423 is a long-acting, peptide-based dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Developed by AmpliMed, the compound is designed to treat metabolic disorders such as obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). By activating both GLP-1 and GIP receptors, AMP-423 aims to provide synergistic effects on glycemic control, insulin sensitivity, and weight reduction, potentially offering superior efficacy compared to mono-receptor agonists. The drug is part of a pipeline of long-acting peptide therapies that utilize proprietary technology to extend circulation time and reduce dosing frequency.

Targets

GLP1R (GLP-1R)GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on AMP-423.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMP-423.

Explore the full profile